Company Overview and News

5
Macquarie eyeing Goldman Sachs’ ReNew Power stake

2018-09-21 livemint
New Delhi: Macquarie Group is among investors who have evinced interest in buying a significant stake from Goldman Sachs Group Inc. in Sumant Sinha-founded ReNew Power Ventures Pvt. Ltd, said two people aware of the development. “Goldman Sachs is interested in divesting some stake in ReNew Power. Some investors, including Macquarie, are looking at it,” said one of the two people cited above, requesting anonymity.
JBK MQBKY GSC GKO TFG PTC ATB MCQEF 532524 GSJ GS GLSSP ENGI GJS MQG

1
Deals Buzz: Ant Financial gets rights to become Zomato’s biggest shareholder

2018-09-11 livemint
New Delhi: Deals Buzz brings to you the top deals news reported from newsrooms across the country
MTCN GKO 513216 NAUKRI APO 532777 UTTAMSTL AMSYF VED MT MT

 
Greenko Group calls off plan to buy Orange Renewable

2018-09-11 livemint
New Delhi: Greenko Group has called off its plan to buy Orange Renewable from Singapore’s AT Capital Group and investment bank Rothschild Inc. has resumed scouting for a buyer for one of India’s largest renewable energy platforms, two people aware of the development said, requesting anonymity. “The contract has expired because of a technical reason,” Greenko Group founder Mahesh Kolli said in response to a query, without giving details.
GKO ENGI PTC 532524

 
RPT-India's small renewables firms fighting consolidation wave

2018-08-21 reuters
MUMBAI, Aug 21 (Reuters) - Small to mid-sized renewable energy companies in India are starting to look like attractive takeover targets as lenders and investors withhold funds, worried by the stiff competition, weak bond markets, low tariffs and high debt besetting the sector.
GKO KMBKY MYT TATAPOWER KOTAKBANK TPCL 500400 500247

 
India's small renewables firms fighting consolidation wave

2018-08-21 reuters
MUMBAI (Reuters) - Small to mid-sized renewable energy companies in India are starting to look like attractive takeover targets as lenders and investors withhold funds, worried by the stiff competition, weak bond markets, low tariffs and high debt besetting the sector.
GKO KMBKY MYT TATAPOWER KOTAKBANK TPCL 500400 500247

 
Tata Power joins race for Equis hydropower projects

2018-07-29 livemint
Mumbai: Tata Power Ltd has expressed interest in buying two hydroelectric power projects in Sikkim owned by Asian infrastructure investor Equis Energy, two people aware of the development said. Equis owns and operates 220 megawatts (MW) of hydro assets in Sikkim through a platform called Hydreq. Mint reported on 1 May that Equis had kick-started a process to sell off these projects.
GKO TATAPOWER TPCL 500400

 
Greenko, others looking to buy Equis#39; India hydropower assets: Report

2018-07-16 moneycontrol
Greenko Group and overseas vehicles utilities are in separate talks to acquire Equis Pte Ltd's Indian hydroelectric assets, according to a Mint report.
GKO

 
Greenko, others in talks for Equis’s India hydropower assets

2018-07-16 livemint
New Delhi: Greenko Group and overseas electric utilities are in separate talks with Equis Pte Ltd to acquire its Indian hydroelectric assets valued at around ₹2,700 crore, two people aware of the development said.
GKO

 
PE firms invest $8.2 bn in June quarter: Report

2018-06-29 thehindubusinessline
Private equity firms invested a record $8.2 billion across 158 deals during the quarter ended June, up 60 per cent over the year-ago period, largely driven by big ticket deals.
GKO SU

 
Steady cash flows, low risk make power transmission segment a safe bet

2018-06-24 livemint
Mumbai: With over 22,000 megawatts (MW) of installed power capacity starved of coal and natural gas supplies, power generation is no longer the hot investment target it used to be. What is taking its place—where everybody now wants a piece of the action—is last-mile delivery of power: transmission.
GKO RELEY TATAPOWER RIFS 539254 RELFF 500390 RELINFRA TPCL RIFA 522287 KALPATPOWR 500400 ADANITRANS

 
Day after Orange deal, Greenko Group gets $450 million from GIC, ADIA

2018-06-05 livemint
Hyderabad/New Delhi: Sovereign wealth funds GIC Holdings Pte Ltd and Abu Dhabi Investment Authority (ADIA) will invest a combined $450 million (around Rs3,000 crore) in Greenko Energy Holdings in one of the largest funding rounds by an Indian clean energy producer.
GKO

2
Greenko Group buys Orange Renewable at billion-dollar valuation

2018-06-03 livemint - 1
Hyderabad/New Delhi: Greenko Group has agreed to buy Orange Renewable from Singapore’s AT Capital Group at an enterprise value of $1 billion, Greenko Group founder Mahesh Kolli said.
GKO TATAPOWER TPCL U96 500400 SCRPF SCRPY

 
Greenko will add $10 billion in assets in 4-5 years: Anil Kumar Chalamalasetty

2018-06-03 livemint
Mumbai: Set up in 2006 by first-generation entrepreneurs Mahesh Kolli and Anil Kumar Chalamalasetty, Greenko Group is backed by Singapore’s sovereign wealth fund GIC Holdings Pte. Ltd and Abu Dhabi Investment Authority. Greenko president and joint managing director Kolli, and Chalamalasetty, the CEO and managing director, in an interview spoke about the rationale behind the acquisition of Orange Renewables, besides sharing their views on the sector.
GKO

 
Tata Power, Actis in fray to buy Essel’s solar power plants

2018-05-21 livemint
Tata Power Ltd and Actis LLP are in separate talks to buy the solar power business of Subhash Chandra’s Essel Infraprojects Ltd, two people aware of the development said.
GKO TATAPOWER TPCL 500400

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to LSE:GKO / GREENKO GROUP PLC on message board site Silicon Investor.

SCRO - HongKong/China PCB mfr.. SCRO - HongKong/China PCB mfr.. SCRO - HongKong/China PCB mfr..